News

Arco Health introduces e-cigarette, new packaging for diet gum

BY Jason Owen

BELLEFONTAINE, Ohio — Arco Health, Inc., makers of Diet-Burst gum, announced last week new packaging designs for its dietary supplement gum, as well as new nicotine replacement products available in July.

The NicoBurst line of products are designed to help smokers end their dependency on smoking traditional cigarettes. The NicoBurst disposable e-cigarette has a traditional tobacoo flavor and provides the same nicotine experience to satisfy a smoker’s cravings. The cigarette replacement product comes after two years of research and development. 

In addition to NicoBurst e-cigarettes, Arco Health will be offering NicoBurst gum and lozenges. NicoBurst chewing gum will be available in 2 mg and 4 mg of nicotine, and NicoBurst lozenges in 2 mg and 4 mg of nicotine.

The company also announced new packaging for its already available Diet-Burst gum, a patented nutraceutical containing Slendesta, an over-the-counter dietary supplement. Diet-Burst gum can be used as a replacement to cigarettes for those smokers who use cigarettes as a means to control their weight. Diet-Burst gum is now available in a two-piece blister pack and an eight-count point-of-purchase display box for retail trade.

NicoBurst electronic cigarettes and DietBurst gum are not smoking cessation products and have not been evaluated by the Food and Drug Administration, nor are they intended to diagnose, treat, cure or prevent any disease. NicoBurst nicotine gum and nicotine lozenges have been evaluated by the Food and Drug Administration and have been approved by the FDA as Nicotine Replacement Therapy products.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

P&G, Stella McCartney announce licensing agreement

BY Antoinette Alexander

GENEVA and LONDON — Procter & Gamble Prestige has inked a licensing deal with Stella McCartney to manufacture and sell designer fragrance products.

Effective Sept. 13, P&G will begin to develop and market new initiatives under the Stella McCartney brand name.

The signing of the Stella McCartney fragrance license is consistent with P&G Prestige’s strategy to grow the business with strong brands with global leadership potential, the company stated. Stella McCartney is complementary to P&G’s existing designer fragrance portfolio and expands upon their strong luxury fragrance brands.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

NACDS-funded report supports policies to boost medication adherence

BY Antoinette Alexander

ARLINGTON, Va. — A new review of the research on the patient-health benefits of improved medication adherence supports the growing momentum behind government and market-based strategies to help patients take medications as prescribed, the National Association of Chain Drug Stores stated on Friday.

“To improve patient outcomes and reduce the financial burden on the healthcare system, policymakers and other healthcare stakeholders should support measures that encourage greater engagement and education with patients to demonstrate the importance of proper medication use,” concluded the report, which was prepared independently by Avalere Health and funded by NACDS.

Titled “The Role of Medication Adherence in the U.S. Healthcare System,” the review includes research on the connection between medication adherence, health outcomes and healthcare system spending, as well as research on major barriers to medication adherence and on examples of initiatives to help improve it.

“When patients struggle to obtain and use medications appropriately, they may limit a drug’s effectiveness, experience poor health outcomes as a result, and raise the overall cost of care in the United States,” the report stated. “For example, recent research has shown that 1) taking drugs as prescribed lowers total healthcare costs by an amount that exceeds the costs of the drugs themselves (Roebuck et al. 2011), and 2) lower spending on prescription drugs may be offset by higher medical services costs (Gaynor et al. 2007).”

The review noted that “the body of evidence on the cost-effectiveness of medication adherence has begun to influence policy,” as evidenced by the Congressional Budget Office’s move in 2012 to associate a reduction in Medicare’s medical service spending when the number of prescriptions filled increases.

“This is the first time the government’s non-partisan legislative scoring agency has credited greater usage of medications with saving healthcare costs, generally, as part of their guidance,” the review stated.
The review noted findings related to the effectiveness of pharmacist-led medication therapy management. It also noted the importance of comprehensive medication reviews, an aspect of MTM in which the pharmacist reviews each individual drug and helps the patient take them appropriately to avoid adverse reactions and to maximize outcomes.

NACDS had endorsed bipartisan legislation in the Senate (S. 557) and in the House of Representatives  (H.R. 1024) — the Medication Therapy Management Empowerment Act — which would improve access to MTM services for senior citizens enrolled in the Medicare Part D program.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...